China Biologic Products Holdings Inc, a leading plasma-based biopharmaceutical company in China, received a $3.9 billion counter offer from an investor consortium led by its former CEO, the group said in a release on Monday. The consortium – led by China Biologic’s former chairman and chief executive David (Xiaoying) Gao – and includes GL Capital Group, Bank of China Group Investment Limited and CDH Investments, has offered to pay US$118 per share, 28.3% above China Biologic’s Friday close. The price …

China Biologic Receives Higher Counter Bid From Investor Group Led By Ex-CEO appeared first on China Money Network.